GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelluna ASA (OSL:ZLNA) » Definitions » Notes Receivable

Zelluna ASA (OSL:ZLNA) Notes Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Zelluna ASA Notes Receivable?

Zelluna ASA's Notes Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Zelluna ASA Notes Receivable Historical Data

The historical data trend for Zelluna ASA's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelluna ASA Notes Receivable Chart

Zelluna ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zelluna ASA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zelluna ASA Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Zelluna ASA Notes Receivable Related Terms

Thank you for viewing the detailed overview of Zelluna ASA's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Zelluna ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Zelluna ASA is a clinical-stage biotechnology company developing novel immunotherapies against cancer and the development of T-Cell Receptor Natural Killer cell therapies for the treatment of solid cancers. The company's current pipeline consists of allogeneic TCR-NK R&D programs ZI-MA4-1, ZI-KL1-1, and ZI-PR-1 targeting well validated antigens expressed across a broad range of solid tumors.

Zelluna ASA Headlines

No Headlines